Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

• Published in: Cell metabolism Vol. 27; no. 4; pp. 740 - 756
• Main Author: Drucker, Daniel J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 03.04.2018
• Subjects: Animals; Blood Glucose - drug effects; body weight; cardiovascular disease; diabetes; Diabetes Mellitus, Type 1 - therapy; Diabetes Mellitus, Type 2 - therapy; drug; Eating - drug effects; G protein-coupled receptor; Glucagon-Like Peptide 1 - adverse effects; Glucagon-Like Peptide 1 - pharmacology; Glucagon-Like Peptide 1 - therapeutic use; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptide-1 Receptor - physiology; Humans; hypertension; Hypoglycemic Agents - therapeutic use; incretin; inflammation; Insulin - metabolism; metabolism; Mice; obesity; Obesity - therapy; Rats; Weight Gain - drug effects; G protein-coupled receptor; body weight; cardiovascular disease; inflammation; incretin; metabolism; diabetes; hypertension; obesity; drug

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion. GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting weight g...